BiBB receives an Intention to Grant for EndoDrill patent in Europe
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from...
Successful introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the University Hospital Center Sestre Milosrdnice in Zagreb, Croatia, has...
EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of EndoDrill®, the world’s first market-cleared motorized endoscopic core biopsy instrument, informs that EndoDrill® is recognized as a promising new EUS product...
BiBBInstruments AB carries out a directed share issue of SEK 10.0 million
The Board of Directors of the cancer diagnostics company BiBBInstruments AB (publ) (“BiBB” or the “Company”) has, based on the authorization granted by the Annual General Meeting on 14 June 2023,...
Successful case studies with EndoDrill GI continue in Norway and Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, informs that clinical evaluation with EndoDrill® GI has started...
EndoDrill presented as New Kid on the Block at ESGE Days
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, informs about the international endoscopy congress in Berlin, ESGE...
Successful clinical pilot study with EndoDrill GI published in peer reviewed scientific journal
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the pilot study EDMX01 with EndoDrill® GI...
First clinical cases with EndoDrill® GI successfully performed at Karolinska University Hospital in Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue acquisition procedures with...
Japanese Patent Office Issues Decision to Grant Patent for EndoDrill Technology
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven endoscopic core biopsy instrument, announces that the Company has received a Decision to...
UC Davis Health reports positive clinical experiences with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven endoscopic core biopsy instrument, announces that clinical partner UC Davis Health has published...
BiBB launches new website
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared motorized endoscopic core biopsy instrument, announces that the Company has launched a new website...
BiBB Receives European CE Mark Approval According to MDR for the Entire EndoDrill Product Family
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which has developed the world’s first electric-driven endoscopic biopsy instrument, announces that the Company has received CE certification for EndoDrill® in...